Biology is an absolute truth.
It holds the answers to diseases that have challenged us for decades.
Learn more
Why use biology-driven methods?
Biological-driven methods allow us to enhance limited clinical assessments with precision and efficiency. By using protein biomarkers and machine learning, we can redefine what is possible in respiratory care by:
Predicting therapeutic response and side effects ahead of time
Monitoring treatment efficacy within shorter timeframes
Differentiating between overlapping conditions
Discovering new targets for drug development
Connecting the dots with the unified airway
The unified airway model connects the nose and lungs through shared immune and inflammatory pathways. Nasal biology mirrors lung health, offering a non-invasive window into respiratory conditions.
Diag-Nose.io leverages this connection together with advanced AI, to develop precision diagnostics and therapies for asthma, COPD, and sinusitis.
A new era of precision medicine
ABEL Microsampler
The ABEL microsampler is a versatile nasal sampling device with an absorptive probe, designed for precise, non-invasive, and omics-grade collection. It enables effortless collection by anyone, anytime, anywhere.
Application
Nasal liquid biopsy for research applications such as respiratory disease, neurodegenerative disorders, oncology, infectious disease and occupational health.
Target Audience
Researchers, clinicians, biobanks and biotech companies.
Estimated Availability
2025 – Pilot access
2026 – Launch
RhinoMAP
The RhinoMAP is a novel precision diagnostics platform that combines nasal microsampling, proteomics, and machine learning to decode airway biology. It aims to predict disease progression, monitor treatment response, and triage between diseases with overlapping symptoms.
Application
AI-powered biological insights to monitor treatment efficacy, predict response and side effects.
Target Audience
Respiratory specialists,
otolaryngologists,
allergists,
biotech companies and researchers
Estimated Availability
2025/26 - Pilot access (Research)
2027 - Pilot access (Clinical)
2028 - Launch
NEBULA
Nebula is a state-of-the-art database for respiratory diseases. It integrates vast datasets from biomarker studies to offer unparalleled insights into the molecular mechanisms of respiratory conditions. By leveraging these datasets, it aims to identify novel therapeutic targets and optimize drug candidate selection.
Application
Biology-driven insights to monitor treatment efficacy, predict treatment response and drug-related side effects.
Target Audience
Biotech companies, researchers and pharmaceutical firms
Estimated Availability
2026 – Pilot access
2027 – Launch
Join our mission to eliminate respiratory disease
Reach out today to learn how you can help make a difference.
Get in touch